

*Medicine optimisation and deprescribing
intervention outcomes for older people
with dementia or mild cognitive
impairment: a systematic review*

Article

Published Version

Creative Commons: Attribution-Noncommercial 4.0

Open Access

Andrews, N., Brooks, C., Board, M., Fraser, S., Latter, S., Aplin, K., McCausland, B., Radcliffe, E., Amin, J., Lim, R. ORCID: <https://orcid.org/0000-0003-1705-1480>, van Leeuwen, E. and Ibrahim, K. (2025) Medicine optimisation and deprescribing intervention outcomes for older people with dementia or mild cognitive impairment: a systematic review. *Drugs & Aging*, 42. pp. 275-294. ISSN 1179-1969 doi: 10.1007/s40266-025-01189-2 Available at <https://centaur.reading.ac.uk/120681/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1007/s40266-025-01189-2>

Publisher: Springer

copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online



Medicine Optimisation and Deprescribing Intervention Outcomes for Older People with Dementia or Mild Cognitive Impairment: A Systematic Review

Nicola Andrews^{1,2} · Cindy Brooks^{1,2} · Michele Board³ · Simon Fraser^{2,4} · Sue Latter¹ · Kirsty Aplin⁵ · Beth McCausland^{5,6} · Eloise Radcliffe^{2,4} · Jay Amin^{5,6} · Rosemary Lim⁷ · Ellen van Leeuwen^{8,9} · Kinda Ibrahim^{2,4}

Accepted: 4 February 2025 / Published online: 11 March 2025
© The Author(s) 2025

Abstract

Background Polypharmacy is common amongst older people with dementia or mild cognitive impairment (MCI), increasing the risk of medication-related harm. Medicine optimisation and deprescribing to reduce polypharmacy is considered feasible, safe and can lead to improved health. However, for those living with dementia or MCI, this can be challenging. This systematic review aimed to summarise the evidence on the outcomes of medicine optimisation and deprescribing interventions for older people with dementia or MCI.

Methods Literature was searched using CINAHL, Embase, Medline, PsychINFO, Web of Science and the Cochrane Library from database inception to January 2024. Papers reporting data specific to people with dementia or MCI from medicine optimisation and deprescribing interventional research studies of any design and in any setting were included. A narrative synthesis was conducted owing to heterogeneity of study designs and outcomes. Quality was assessed using the Mixed Methods Appraisal Tool.

Results A total of 32 papers reporting on 28 studies were included, with samples ranging from 29 to 17,933 patients and a mean patient age ranging from 74 to 88 years. Of the studies, 60% were undertaken in long-term care settings. Involvement of patients and/or carers in interventions was limited. Papers were grouped as either incorporating a medication review component ($n = 13$), education component ($n = 5$) or both ($n = 14$). Studies primarily focussed on medication-related outcomes, generally showing a positive effect on decreasing the number and improving appropriateness of medications. Fewer papers reported clinical outcomes (behavioural and psychological symptoms of dementia, falls, quality of life and cognition) with mixed findings. A reduction or no change in mortality or hospital attendance demonstrated safety of the interventions in the few papers reporting these outcomes. The quality of the evidence was mixed.

Conclusions Medicine optimisation and deprescribing interventions generally reduced the number and increased the appropriateness of medications, and although less frequently reported, these interventions seemed to be safe and showed an absence of worsening of clinical outcomes. This review highlights a need for further research, particularly in people with dementia or MCI living at home, with more focus on clinical outcomes and a greater involvement of patients and informal carers.

Protocol Registration The protocol was published in the International Prospective Register of Systematic Reviews (PROSPERO) [Ref: CRD42023398139].

1 Background

In developed countries, most people with dementia or mild cognitive impairment (MCI) have multiple long-term conditions and are prescribed five or more regular medications, which is the most common definition of polypharmacy [1, 2]. Polypharmacy in people living with dementia

is associated with increased risk of drug–drug interactions, falls, cognitive decline and serious adverse events such as emergency department attendance, hospitalisation and death [3, 4]. Polypharmacy in this group also increases the risk of potentially inappropriate medication (PIM) [5], a term commonly used to refer to medications for which potential risks outweigh potential benefits and that have a higher risk of adverse drug events [6, 7]. Medication management on a

Key Points

Medicine optimisation and deprescribing interventions for people with dementia or mild cognitive impairment show a trend towards reducing numbers of medications and improving appropriateness of medication.

There was limited evidence on clinical and safety outcomes and limited involvement of patients and informal carers.

Most studies were conducted on medicine optimisation and deprescribing interventions, focussing on psychotropic medications and people in residential care, with very few studies conducted in primary care settings.

daily basis is a complex and challenging activity involving both older people with dementia and their carers [8, 9].

To reduce the potential harm associated with polypharmacy in this population, medicine optimisation and deprescribing are recommended [10]. Deprescribing is the process of tapering or reducing doses or stopping or switching drugs, with the goal of managing polypharmacy and reducing the risk of adverse outcomes [11]. There is evidence that deprescribing across a wide range of conditions, medications and care settings, and using different deprescribing tools, is feasible, safe and can benefit patients [12–17]. Medication-induced harm is now classified as one of the World Health Organisation's global health priorities and a national priority in many countries, including the UK, Canada, Australia and the USA [18]. Encouraging open and honest conversations about medication is important to reduce and prevent this harm [18, 19]. Optimising medications through deprescribing has the potential to improve outcomes for people living with dementia [20] and may reduce the risk of MCI progressing to dementia [21].

Several systematic reviews have been published to summarise the effectiveness of medicine optimisation and deprescribing interventions in older adults in general, with some focussing on health-related, safety and cost outcomes [12, 17, 22] or on specific clinical settings [15]. One review of the impact of deprescribing among people living with frailty reported that it is feasible, acceptable and can lead to benefits in terms of cognition and medication appropriateness [23]. Reviews report that medicine optimisation and deprescribing could be safe and can benefit patients [12–17]. However, there is limited direct evidence to inform medicine optimisation and deprescribing in older adults with dementia or MCI, specifically. Optimising medications amongst this population is complicated owing to difficulties in comprehension,

challenges in communication and involvement of informal carers [24].

A recent survey in the USA of 422 older people with dementia reported that 87% were willing to stop one or more of their medications if advised by their doctors, and 50% were uncomfortable taking five or more medications [25]. Yet, a narrative review published in 2021 found limited evidence of involvement of the person with dementia or their carer in decisions about their medicines [20] and reported that most research concentrated on medication-related outcomes (e.g. discontinuation of high-risk medications) rather than clinical outcomes that have a direct impact on a person's well-being, such as cognition and falls. The authors recommended that more research be conducted on the impact of deprescribing in this population across clinical settings. Reviews in this field have also focussed primarily on identifying barriers and facilitators of deprescribing in this population and less on the effects of deprescribing interventions [24, 26]. Therefore, the aim of this systematic review was to explore the effects of medicine optimisation and deprescribing interventions specific to older people with dementia or MCI.

2 Methods

The methods recommended by the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement were used to complete the review [27]. It was registered on the international prospective register of systematic reviews (PROSPERO), ID no. CRD42023398139.

2.1 Data Sources and Searches

The following electronic databases were searched for papers published from database inception to search date (initial search 3 February 2023; updated 26 January 2024): CINAHL, Embase, Medline, PsychINFO, Web of Science and the Cochrane library. The search strategy using keywords, including dementia, mild cognitive impairment, deprescribing, medicines optimisation, polypharmacy and inappropriate prescribing, was developed with a senior librarian (Online Resource 1). Reference lists of included papers were searched for further potentially relevant studies.

2.2 Screening and Study Selection

As the review focussed on interventions, the population, intervention, comparator, outcomes, study design (PICOS) framework was used to develop the inclusion and exclusion criteria, outlined in Table 1. The citations identified from the

searches were screened in three stages using these eligibility criteria.

Firstly, titles were independently double screened using Excel. N.A. screened all titles and B.M., K.A. and K.I. each screened a subset of titles, with citations excluded only where there was agreement between two authors. Abstracts were then independently screened by five authors (N.A., J.A., C.B., S.F. and B.M.) using Rayyan™ software [28], which facilitates and expedites collaborative and blind screening and selection of papers, with any disagreement resolved by discussion. Full text papers of those included at this stage were each independently screened by eight authors (N.A., K.A., C.B., S.F., K.I., E.v.L., R.L. and S.L.), with disagreement resolved by discussion. Consistency of criteria application was then checked by N.A., C.B. and K.I.

2.3 Quality Assessment

The Mixed Methods Appraisal Tool (MMAT) [29], developed for quality appraisal in systematic reviews of mixed studies, was used to assess the quality of the included papers. This allowed the same tool to be used for all the papers, despite heterogeneity in study designs. Quality assessment was completed by two authors independently (M.B. and E.R.), with final ratings agreed by discussion. Each paper was given a score from one to five, with lower scores

indicating lower quality studies. Studies were not excluded on the basis of quality; rather, this was used to inform the interpretation of the data.

2.4 Data Extraction

Data from included studies were extracted into a form developed in Microsoft Excel and piloted with two papers. Data extraction was completed independently by N.A. and six other authors (K.A., M.B., C.B., K.I., S.L. or R.L.). Disagreements were resolved through consensus discussion between N.A., C.B. and K.I. Data extracted included: year of publication, country, setting, number and characteristics of participants, description of the deprescribing intervention and any comparator, length of follow-up, medications most frequently deprescribed, deprescribing tools used and involvement of patients and carers in the intervention and outcomes of deprescribing.

2.5 Data Synthesis

Owing to the heterogeneity of study designs and outcome measures, meta-analysis of effect estimates was not possible, and narrative synthesis was conducted using the Synthesis Without Meta-analysis (SWiM) guideline [30]. Studies were grouped according to intervention type, with groupings

Table 1 Inclusion and exclusion criteria for the systematic review

PICOS	Inclusion criteria	Exclusion criteria
Population	Older people with a diagnosis of any type of dementia or mild cognitive impairment or who provide care (formal or informal) to people with a diagnosis of dementia or mild cognitive impairment (determined by study authors) Or Studies with a population that includes older people with a diagnosis of any type of dementia or mild cognitive impairment or those who provide care to this population amongst others, where the data for the target population can be separated from the broader population	People with cognitive impairment but who do not have a diagnosis of dementia or mild cognitive impairment or people who provide care (formal or informal) to people with cognitive impairment owing to other causes
Intervention	Any intervention in any setting that aims to deprescribe medication or involves medicine optimisation or medicine review, including dose reduction/tapering, stopping or switching drugs	Any multi-dimensional interventions that include a deprescribing/medicine optimisation/medicine review element alongside other intervention components, where the data relating to the deprescribing element cannot be separated from the other components
Comparator	Any or no comparator	
Outcomes	Any outcome, including (but not restricted to) safety of deprescribing, clinical outcomes, medication-related outcomes, feasibility of deprescribing, acceptability and cost-related outcomes At least one patient-related outcome, defined as outcomes measured using individual patient data ^a	No patient-related outcomes, defined as outcomes measured using individual patient data ^a
Study design	Interventional research studies with any design and in any setting	Quality improvement, service evaluation or audit ^a
Search limits	Any paper published from database inception to date of search Any language	

^aCriteria added after initial protocol publication, as per amended PROSPERO record

agreed upon once papers had been identified. Outcome data were categorised into three categories: medication-related outcomes, clinical-related outcomes and safety outcomes. Both medication and clinical outcomes were based on a recent review of outcomes of deprescribing interventions [31]. Safety outcomes included mortality, hospitalisations and emergency department visits as these are the most commonly used outcome measures in deprescribing literature [23, 32].

Outcome data were summarised and then tabulated according to intervention type and direction of effect for comparison.

3 Results

The searches identified 8825 individual citations of which 163 were selected for full text assessment and 29 papers were eligible for inclusion in the review. An additional three eligible papers were identified from the screening of reference lists of included papers, with a total of 32 papers included in this review (Fig. 1). Translation of one potentially eligible non-English paper was unavailable.

3.1 Study Characteristics

The 32 papers included in this review reported findings from 28 unique research studies (Table 2). All included papers were published between 2013 and 2024. Studies were conducted in 12 countries: Canada ($n = 6$), Spain ($n = 6$), the USA ($n = 5$), Australia ($n = 2$), the UK ($n = 2$), France ($n = 1$), Ireland ($n = 1$), Italy ($n = 1$), Japan ($n = 1$), Sweden ($n = 1$), Taiwan ($n = 1$) and the Netherlands ($n = 1$). Over half of the papers reported studies completed in long-term residential care settings ($n = 19$). Papers also reported studies undertaken in primary care or community healthcare services ($n = 6$), hospital inpatient settings ($n = 5$), hospital outpatient settings ($n = 1$) and across multiple settings ($n = 1$). Papers primarily focussed on deprescribing of either psychotropic medications ($n = 16$, all but one in long-term care settings) or PIMs ($n = 9$). Eight papers reported randomised controlled trials (RCTs). The length of follow-up ranged from 11 days (mean length of hospital admission) to 2 years, with most papers reporting follow-up periods of 6 ($n = 12$), 9 ($n = 5$) or 12 months ($n = 5$). Attrition was reported in half of the papers ($n = 16$) and ranged from 8% to 51%, with the main reasons cited being death or a change in the care setting of the participants. The assessed quality of the papers was variable. Quality issues were highlighted with quantitative studies that did not use randomisation to allocate to comparison groups (non-randomised studies) more frequently than with RCTs, quantitative descriptive studies and mixed methods studies. These issues particularly

related to confounders and sample representativeness, with non-randomised studies accounting for more than half of the studies ($n = 16$).

In total, 11 of the 32 papers reported interventions that included active involvement of patients and/or informal carers in the medicine optimisation or deprescribing process [32–42]; only one [39], a medication review and education intervention, incorporated shared decision-making. The study protocol reports dialogue between the professionals, person with dementia and their carer during the medication review [43]. In addition, nine papers reported person-centred deprescribing interventions [32–38, 41, 42]; however, it is not possible to determine from the papers whether this involvement implemented shared decision-making principles. Another paper reported an intervention [40] that empowered patients to lead deprescribing decision-making through the use of educational materials.

3.2 Participant Characteristics

Study sample sizes ranged from 29 to 17933 patients. Participants were predominately older people, with the mean patient age ranging from 74 to 88 years. However, this does not preclude a small minority of the study populations from being aged under 65 years; one study explicitly stated that 4% of the participants were under 65 years [44], with an age range of 55 to 99 years (mean of 84 years) provided in one study set in long-term care [45, 46]. Moreover, seven studies explicitly recruited populations aged 65 years and over [32–34, 41, 47–51] and one recruited participants aged 60 years and over [38]. The percentage of female patients ranged from 51% to 79%, except in two outlier studies (one recruited only male patients [52], whilst the other had 22% female patients [47]). In total, 26 papers reported on outcomes for people with dementia, 5 for people with either dementia or MCI and 1 for people with MCI only. Participant dementia type was rarely provided, with this information only provided in five studies [45, 46, 48, 49, 51, 53, 54]. The diagnosis of dementia or MCI was determined by the study authors, mostly using medical records, including documented diagnosis, prescription of anti-dementia medication or other relevant information. Some study authors also used one or more of the following criteria to determine a diagnosis of dementia or MCI: (1) being a resident in a long-term care dementia unit, (2) assessment by specialist professionals and (3) the use of tools to assess disease severity, including the Clinical Dementia Rating Score, Functional Assessment Staging Test, Global Deterioration Scale, Mini Mental State Examination and Montreal Cognitive Assessment.




Fig. 1: PRISMA flowchart

3.3 Types of Interventions

Owing to heterogeneity of outcome measures and study designs, papers were grouped according to the intervention investigated as either “medication review and healthcare professional education interventions” (14 papers), “medication review interventions” (13 papers) or “patient, carer and/or healthcare professional education interventions” (5 papers), although there was considerable variation between interventions in each group.

Medication review and healthcare professional education interventions (reported in 14 papers) [35–39, 45, 46, 50, 52, 55–59], all implemented in long-term care settings, involved formal education that included a focus on deprescribing delivered either through taught sessions or by provision of information. The medication review component of the interventions was led by either a doctor, pharmacist or a multi-disciplinary (MDT) team.

Medication review interventions (reported in 13 papers) [34, 41, 42, 44, 47–49, 54, 60–62] were either a standalone intervention ($n = 10/13$) or combined with other components (such as a new model of coordinated primary care or proactive medication monitoring), with data specifically relating to the medication review reported. These were implemented in a range of settings. In total, seven papers reported medication reviews led by pharmacists, four papers reported MDT-led reviews and one paper reported an automated review using a computer algorithm triggering alerts to professionals. There were no details provided of the medication review process in one paper.

Patient, carer and/or healthcare professional education interventions (reported in five papers) all included formal education relating to deprescribing as the only intervention [32, 33, 40, 63, 64]. Two reported studies were completed in long-term care settings and three in primary care or community settings. These involved either educational sessions

Table 2 Characteristics of the papers included in the review

First author and year of publication	Country and setting	Study design	Sample size	% dementia or MCI and type of dementia	Intervention	Comparator	Follow-up	Medication class	Deprescribing tool	Quality score ^a
<i>Medication review and healthcare professional education interventions</i>										
Ballard 2016 [55]; Ballard 2017 [50]	UK Long-term care	Cluster 2 × 2 × 2 factorial randomised controlled trial	277	100% dementia / types not specified	Training of staff in person-centred care and physician-led antipsychotic review.	Multiple comparators	9 mths	Antipsychotics	National or provincial guidelines	4
Brodaty 2018 [56]	Australia Long-term care	Repeated measures, longitudinal, single-arm study	139	98.5 % dementia / types not specified	Education of MDT and pharmacist-developed individualised deprescribing protocol implemented.	Pre-post	12 mths	Antipsychotics	National or provincial guidelines	4
Cossette 2020 (phase 1) [35]	Canada Long-term care	Mixed methods study	464	100 % dementia / types not specified	Knowledge mobilisation strategy and antipsychotic medication review using provincial guidelines.	None	9 mths	Antipsychotics	National or provincial guidelines	3
Cossette 2022 (phase 2) [36]	Canada Long-term care	Prospective, closed cohort, scale-up study	4087	100% dementia / types not specified	As for phase 1 but included a train the trainer approach owing to scale-up.	Phase 1	9 mths	Antipsychotics	National or provincial guidelines	4
Kröger 2023 [38]	Canada Long-term care	Pragmatic, non-randomised controlled study	123	100% dementia / types not specified	MDT knowledge exchange session and leaflet for families plus pharmacist-led medication review.	Usual care	6 mths	Any medication	Intervention specific	4

Table 2 (continued)

First author and year of publication	Country and setting	Study design	Sample size	% dementia or MCI and type of dementia	Intervention	Comparator	Follow-up	Medication class	Deprescribing tool	Quality score ^a
Maidment 2020 [39]	UK Long-term care	Open label (non-blinded), mixed methods feasibility study	29	100% dementia / types not specified	MDT-led medication review involving resident and their carer plus staff training on BPSD treatment.	Meds change vs no meds change	6 mths	Psychotropics	Not specified	3
Massot Mesquida 2019 [57]	Spain Long-term care	Prospective, multi-centre, quasi-experimental, longitudinal, pre-post study	240	100% dementia / types not specified	A GP and pharmacist were trained, who led medication reviews on the basis of BPSD management guidelines.	Pre-post	6 mths	Psychotropics	Intervention specific	3
Muniz 2020 [58]	Spain Long-term care	Observational, longitudinal, prospective validation study	288	71.4% dementia / types not specified	Training of MDT and use of CHROME criteria to guide quality prescribing of psychotropic medicines.	None	2 yrs	Psychotropics	Intervention specific	3
Muniz 2021 [59]	Spain Long-term care	Observational, prospective, two-wave, pilot study	171	84.8% dementia / types not specified; 15.2% MCI	Doctors were trained in the CHROME criteria, using these to reassess diagnoses and de-prescribe.	Pre-post	12 mths	Psychotropics	Intervention specific	3
van der Spek 2018 [46]; Smeets 2021 [45]	The Netherlands Long-term care	Cluster randomised controlled pragmatic trial with two parallel groups	380	AD (33%), Vascular (15%), Mixed AD/vascular (11%), other (41%)	Repeated MDT-led medication reviews following national guidelines, after initial education phase.	Usual care	18 mths	Psychotropics	National or provincial guidelines	5

Table 2 (continued)

First author and year of publication	Country and setting	Study design	Sample size	% dementia or MCI and type of dementia	Intervention	Comparator	Follow-up	Medication class	Deprescribing tool	Quality score ^a
Wilchesky 2018 [37]	Canada Long-term care	Quasi-experimental feasibility pilot study	44	100% dementia / types not specified	MDT knowledge exchange session and leaflet for families plus pharmacist-led medication review.	Pre-post	Mean 104 days	Any medication	Intervention specific	4
Yeh 2013 [52]	Taiwan Long-term care	Prospective, open-label, case-control cohort study	67	100% dementia / types not specified	Education materials mailed to GPs, with anticholinergic medications tapered or replaced.	Usual care	3 mths	Anti-cholinergics	CRACHS	3
<i>Medication review interventions</i>										
Andrew 2018 [60]	Canada Long-term care	Observational pre-post study	159 pre 370 post	55.9% pre & 72.8% post with dementia / types not specified	A multi-component intervention including a biannual pharmacist-led medication review.	Pre-post	N/A	PIMs	Beers	5
Bravo-José 2019 [53]	Spain Long-term care	Prospective, single centre, before-after study	35	AD (46%), vascular (14%), non-specific (40%)	Gradual tapering of antipsychotic treatment.	Pre-post	6 mths	Antipsychotics	Intervention specific	3
Coli 2022 [48]	USA Hospital outpatient	Prospective, observational study	180	AD (32%), vascular (7%), Lewy body (2%), Parkinson dementia (2%), other (38%), MCI (28%)	Pharmacist-led medication review, recommendations made prior to the patients' next appointment.	Pre-post	6 mths	PIMs	Beers/STOPP/ Anticholinergic burden scale	4
Gustafsson 2017 [51]; Gustafsson 2018 [49]	Sweden Hospital inpatient	Randomised controlled trial	429	AD (31%), vascular (17%), other or unspecified dementia (52%)	Pharmacist-led medication reconciliation and medication review.	Standard care	6 mths	PIMs	National or provincial guidelines	5

Table 2 (continued)

First author and year of publication	Country and setting	Study design	Sample size	% dementia or MCI and type of dementia	Intervention	Comparator	Follow-up	Medication class	Deprescribing tool	Quality score ^a
Jaidi 2018 [54]	France Hospital inpatient	Prospective, single centre study	125	AD (57%), Mixed AD / vascular (26%), vascular (14%), Lewy body (4%)	Substitution of medications potentially inappropriate owing to anticholinergic burden.	Pre-post	Admission length	Anti-cholinergics	Anticholinergic cognitive burden scale	4
Kable 2023 [61]	Australia Hospital inpatient	Non-randomised experimental study with pre-post design	628	100% dementia or MCI / dementia types not specified	Medication reconciliation and review by hospital pharmacist on admission and prior to discharge.	Pre-post; control	3 mths	PIMs	Beers/modified anticholinergic burden score	4
Liu 2022 [42]	USA Community	Secondary analysis of a multi-centre, single-blind randomised controlled trial	490	100% dementia / types not specified	Protocol-guided, interdisciplinary medication review, with proactive medication monitoring.	Usual care	12 mths	PIMs	Beers	4
Molist Brunet 2014 [34]	Spain Hospital inpatient	Non-experimental pre-post study	73	100% dementia / types not specified	MDT-led systematic evaluation of medication profiles and development of therapeutic plans.	Pre-post	Admission length	Any medication	Beers/STOPP	4
Pearson 2021 [62]	USA Primary care	Retrospective, descriptive analysis of two clinical initiatives (<i>only one eligible for review</i>)	40	100% dementia / types not specified	Pharmacist-led medication reconciliation and review, focussed on medications impacting cognition.	Pre-post	6 mths	PIMs	Beers	2

Table 2 (continued)

First author and year of publication	Country and setting	Study design	Sample size	% dementia or MCI and type of dementia	Intervention	Comparator	Follow-up	Medication class	Deprescribing tool	Quality score ^a
Sakakibara 2015 [47]	Japan Community	Non-randomised controlled study	50	100% dementia / types not specified	Prescription drugs were reduced as proposed by a pharmacist.	Usual care	6 mths	Any medication	Not specified	3
Silva-Almodovar 2020 [44]	USA Cross-settings	Retrospective, observational cohort analysis of a database	17933	100% dementia / types not specified	Computer algorithm-led review of prescription claims data, with alerts sent to prescriber.	None	12 mths	PIMs	Beers	3
Weeks 2019 [41]	Spain Long-term care	Quasi-experimental, retrospective, matched, controlled, observational analysis	1653	100% dementia / types not specified	MDT-led medication review OR Use of STOPP/START criteria OR patient "Decision Aid" use.	Matched controls	4 wks	Psychotropics	Intervention specific	4
<i>Patient, carer, and/or healthcare professional education interventions</i>										
Bayliss 2022 [33]; Boyd 2024 [32]	USA Primary care	Pragmatic cluster randomised controlled trial	1433	88.1% dementia / types not specified; 21.9% MCI	Educational brochure mailed to patients before appointment; tip sheets provided to clinicians.	Usual care	6 mths	PIMs	Beers	4
Martin 2017 [40]	Canada Community	Post-hoc analysis of randomised, double-blind, wait-list controlled trial	261	46.7% MCI	Educational brochure including a deprescribing tool mailed to patients.	MCI vs no MCI	6 mths	Benzo-diazepines	Intervention specific	5

Table 2 (continued)

First author and year of publication	Country and setting	Study design	Sample size	% dementia or MCI and type of dementia	Intervention	Comparator	Follow-up	Medication class	Deprescribing tool	Quality score ^a
Pasina 2016 [63]	Italy Long-term care	Quantitative, multi-centre, prospective pilot study	295	66.2% dementia / types not specified	MDT-led educational interventions and training on use of a digital prescription support system.	Pre-post	9 mths	Psychotropics	Beers/STOPP/ Anticholinergic cognitive burden scale	3
Walsh 2022 [64]	Ireland Long-term care	Mixed methods feasibility study	43	57% dementia / types not specified	Education of nursing home staff (direct or via 'opinion leaders'); academic detailing with GPs.	None	3 mths	Antipsychotics	Intervention specific	4

AD Alzheimer's disease, *BPSD* behavioural and psychological symptoms of dementia, *CHROME* Chemical Restraints Avoidance Methodology, *CRACHS* clinician-rated anticholinergic score, *MCI* mild cognitive impairment, *MDT* multidisciplinary team, *Mths* months, *PIMs* potentially inappropriate medications, *START* Screening Tool to Alert to Right Treatment, *STOPP* Screening Tool of Older Person's potentially inappropriate Prescriptions, *Wks* Weeks, *Yrs* Years

^aScore calculated using 'yes' responses to the five quality appraisal questions for the appropriate study type of the Mixed Methods Appraisal Tool [29]

or the provision of educational materials: two interventions were solely for professionals, one intervention was solely for patients and two interventions involved patients, informal carers and professionals.

Variation in intervention characteristics within these groups are explored in the synthesis narrative and more details about each individual intervention is provided in Online Resource 2. A range of deprescribing tools was used across all intervention group types, including Beers criteria [65], the Screening Tool of Older Person's Prescriptions (STOPP) [66], anticholinergic burden scores, national or provincial guidelines, and intervention specific tools (Table 2). These were used either to inform the intervention, such as medication review or educational content, or to identify inappropriate medications for the purposes of measuring study outcomes.

3.4 Outcomes of Interventions

To assess effects of the interventions, the outcomes have been grouped into medication-related outcomes (reported in 28/32 papers), clinical-related outcomes (reported in 19/32 papers), and safety-related outcomes (defined as reported adverse events, hospital admission and/or mortality; reported in 10/32 papers) and are outlined in Sections 3.4.1–3.4.3. Less than four papers reported outcomes related to feasibility and/or costs, and measurements were too varied to usefully synthesise.

The direction of effect of the interventions on each outcome is summarised in Table 3 (full details are provided in Online Resource 3).

3.4.1 Medication-Related Outcomes

3.4.1.1 Psychotropic Medication In total, 17 papers reported impact on psychotropic prescribing in general ($n = 6$) or specific medication classes [such as antipsychotics ($n = 6$) or benzodiazepines ($n = 1$)] from across all intervention groups. The studies were primarily completed in long-term care settings ($n = 14$) [35–38, 41, 45, 53, 55–59, 63, 64], with two in community settings [40, 42] and one in an inpatient setting [61]. Effects were not measured in the same way across the studies. The most common measures used were the percentage of participants for whom psychotropic medications were stopped or reduced ($n = 7$) and the change in the mean number of psychotropic medications per participant ($n = 5$).

A decrease in at least one class of psychotropic medication was reported in 12 out of the 17 papers [35, 36, 40–42, 53, 55–59, 63], with no obvious correlation between the type of intervention and effect on psychotropics. Moreover, 5 out of the 17 papers reported either no effect ($n = 3$) or an increase in the number of prescribed psychotropic

drugs ($n = 2$), although a second paper from one study showed a reported improvement in psychotropic appropriateness [46].

3.4.1.2 Potentially Inappropriate Medications Nine papers reported outcomes related to PIMs [33, 37, 38, 42, 44, 48, 49, 61, 62], with the majority of interventions incorporating a medication review component ($n = 8$). Six papers defined PIMs on the basis of the Beers criteria [65] either on its own [33, 42, 44, 62] or in combination with anticholinergic burden scoring [61] or anticholinergic burden scoring and STOPP [49]. One paper used Swedish national quality indicators [49], and the other two used criteria developed with clinical experts, specifically for older adults with severe dementia [37, 38]. Outcome measures varied, including changes to total numbers of PIMs, changes to numbers of patients taking one or more PIMs, and discontinuation rates. Six out of nine papers reported a significant reduction in the number of PIMs post intervention [37, 42, 44, 48, 49, 62], primarily medication review interventions ($n = 5$). No effect was reported in three papers [33, 38, 61]. The interventions were implemented across all three intervention groups and the full range of settings, with no association between intervention type or setting and effect on outcome measure.

3.4.1.3 Total Number of Medications Seven papers reported on changes to total number of medications prescribed [33, 34, 37, 38, 42, 47, 60]. Four out of the seven papers (three combination medication review and education interventions and one medication review intervention) [34, 37, 47, 60] reported a decrease in the total number of medications post-intervention. The decrease in total medications ranged from a mean of 1.05 to 2.6 per participant across these studies. Three papers (one of each type of intervention) did not report a significant decrease in the number of medications [33, 38, 42]. Of note, the types of medications included in the total medication counts were not consistent across the seven studies. For example, one included just regular medications [37], another included both regular and pro re nata (PRN) medications [60], and one included any medication prescribed for at least 28 days [33].

3.4.1.4 Anticholinergic Burden Five papers measured changes in anticholinergic burden (ACB), and all interventions involved medication review, either with or without education [42, 48, 52, 54, 61]. Four studies assessed anticholinergic burden using the Anticholinergic Cognitive Burden Scale, with one using a version modified for use in Australia [61]. The other study [52] used the Clinician-Rated Anticholinergic Score (CRACHS). Three studies showed a reduced ACB, whilst two studies [42, 61] showed no effect, with no association with the ACB assessment tool used.

3.4.2 Clinical-Related Outcomes

3.4.2.1 Behavioural and Psychological Symptoms of Dementia (BPSD) Outcomes related to BPSD were measured in 12 papers, across all three intervention groupings, primarily in long-term care settings [35–39, 45, 53, 55, 56, 59, 64], except one undertaken in an inpatient environment [54]. All studies measured changes in BPSD using the Neuropsychiatric Inventory (NPI) and/or the Cohen–Mansfield Agitation Inventory (CMAI), with mixed findings across those assessed with each tool. Most of the studies focussed on optimising psychotropic medication ($n = 9$) [35, 36, 39, 45, 53, 55, 56, 59, 64]. Follow-up ranged from 3 to 12 months, except in two studies, which had variable follow-up periods: one reporting a mean follow-up period of 104 days [37] and the other being the length of hospital inpatient admission [54].

Half of the papers (6/12) reported that the intervention had no effect on BPSD [37, 39, 45, 53, 56, 64]. Although one of these interventions, a combined medication review and education intervention focussed on any medication, showed no effects in the pilot study [37], a subsequent larger study reported improvements in BPSD [38]. Four other papers reported improvements post-intervention that included a medication review either alone or in combination with education [35, 36, 38, 54, 59]. Of these, three focussed on optimising psychotropic medication and one focussed on optimising anticholinergic medication [54]. The last paper reported mixed effects, finding that antipsychotic medication

review combined with education led to no effect on agitation assessed using CMAI but a worse outcome on overall neuropsychiatric symptoms measured using NPI [55]. There was no association between follow-up length and effect on outcome measure.

3.4.2.2 Falls Impact on falls was assessed in six papers, across all intervention groups, with most showing no significant change in either number of falls or fall risk. Five of the papers focussed on optimising psychotropic medication in long-term care settings [35, 36, 41, 56, 64] and one focussed on PIMs in a hospital outpatient setting [48]. One paper combined medication review and education intervention which showed little impact on falls in an initial study involving 24 long-term care wards [35] but a significant reduction in falls when scaled up to 329 wards [36]; both studies had a follow-up period of 9 months.

There was variation in how falls were assessed, with most using number of actual falls in either the previous month ($n = 3$) or 6 months ($n = 1$). One paper measured risk of falls, which was determined using patient self-reported feelings of unsteadiness documented in medical records, and another reported the odds ratio for patient falls. Length of follow-up also varied significantly, ranging from 4 weeks [41] to 12 months [56].

3.4.2.3 Quality of Life Three papers measured the impact on health-related quality of life (HRQOL) by using a validated proxy measure, with mixed results. Two papers

Table 3 Direction of effect of intervention on study outcomes for each included paper

First author and year of publication (Intervention name)	Medication-related outcomes				Clinical-related outcomes				Safety-related outcomes	
	<u>Psychotropic drugs</u> (Effect on amount of psychotropic medication)	<u>PIMs</u> (Effect on number of PIMs)	<u>Total medication</u> (Effect on total number of medications)	<u>Anti-cholinergic Burden</u> (Effect on anticholinergic burden score)	<u>BPSD</u> (Effect on NPI or CMAI scores, decrease indicating improvement in BPSD)	<u>Falls</u> (Effect on number of falls or falls risk)	<u>HRQoL</u> (Effect on HRQoL measure score; increase indicating improvement)	<u>Cognition</u> (Effect on cognitive assessment score; increase indicating improved cognition)	<u>Mortality</u> (Effect on mortality rate or deaths attributable to intervention)	<u>Hospital attendance</u> (Effect on emergency department attendances or hospitalisations)
MEDICATION REVIEW AND HEALTHCARE PROFESSIONAL EDUCATION INTERVENTIONS										
Ballard 2016 (WHELD) [55]	Decrease				Increase (NPI) / No effect (CMAI)				No effect	
Ballard 2017 (WHELD) [50]							Decrease			
Brodsky 2018 [56]	Decrease				No effect (NPI & CMAI)	No effect		No effect		No effect
Cossette 2020 (OPUS-AP) [35]	Decrease				Decrease (CMAI)	No effect			Decrease	
Cossette 2022 (OPUS-AP) [36]	Decrease				Decrease (CMAI)	Decrease				
Kröger 2023 (OptimaMed) [38]	Increase	No effect	No effect		Decrease (CMAI)					
Maidment 2020 [39]					No effect (NPI)					
Massot Mesquida 2019 [57]	Decrease									
Muniz 2020 (CHROME) [58]	Decrease									
Muniz 2021 (CHROME) [59]	Decrease				Decrease (NPI)		No effect			
Smeets 2021 (PROPER) [45]	Increase				No effect (NPI & CMAI)					
van der Spek 2018 (PROPER) [46]										
Wilchesky 2018 (OptimaMed) [37]	No effect	Decrease	Decrease		No effect (CMAI)					
Yeh et al 2013 [52]				Decrease				No effect		No effect
MEDICATION REVIEW INTERVENTIONS										
Andrew 2018 [60]			Decrease							
Bravo-José 2019 [53]	Decrease				No effect (NPI)					
Coli 2022 [48]		Decrease		Decrease		No effect		Decrease		

Table 3 (continued)

	Medication-related outcomes				Clinical-related outcomes				Safety-related outcomes	
Gustafsson 2017 [51]									No effect / Decrease ^a	
Gustafsson 2018 [49]		Decrease							No effect	
Jaidi 2018 [54]				Decrease	Decrease (NPI)					
Kable 2023 [61]	No effect	No effect		No effect						
Liu 2022 [42]	No effect / Decrease ^b	Decrease	No effect	No effect						
Molist Brunet 2014 [34]			Decrease							
Pearson 2021 [62]		Decrease								
Sakakibara 2015 [47]			Decrease				No effect / Increase			
Silva-Almodovar 2020 [44]		Decrease								
Weeks 2019 [41]	Decrease					No effect			No effect	
PATIENT, CARER, AND/OR HEALTHCARE PROFESSIONAL EDUCATION INTERVENTIONS										
Bayliss 2022 (OPTIMIZE) [33]		No effect	No effect						No effect	No effect
Boyd 2024 (OPTIMIZE) [32]									No effect	No effect
Martin 2017 [40]	Decrease									
Pasina 2016 [63]	Decrease									
Walsh 2022 [64]	No effect				No effect (NPI)	No effect				

^aNo effect on drug-related readmission or time to drug-related readmission; significant reductions were found after adjustment for heart failure.

^bNo effect overall, positive effect for subgroup who had benzodiazepines deprescribed.

BPSD Behavioural and Psychological Symptoms of Dementia

CMAI Cohen-Mansfield Agitation Inventory

HRQoL Health-Related Quality of Life

NPI Neuropsychiatric Inventory

PIMs Potentially Inappropriate Medications

BPSD behavioural and psychological symptoms of dementia, CMAI Cohen-Mansfield Agitation Inventory, HRQoL health-related quality of life, NPI neuropsychiatric inventory, PIMs potentially inappropriate medications

^aNo effect on drug-related readmission or time to drug-related readmission; significant reductions were found after adjustment for heart failure

^bNo effect overall, positive effect for subgroup who had benzodiazepines deprescribed

found no effect, one found a combined medication review and education intervention focussed on optimising psychotropics [59] and one found a medication review intervention focussed on any medication [47]; study follow-up periods were 12 months and 6 months, respectively. However, although Sakakibara et al. [47] found no effect overall, sub-analysis showed there was a significant improvement in HRQOL scores for those who underwent benzodiazepine deprescribing. The third paper, reporting a combined medication review and education intervention with a 9-month follow-up period, found that deprescribing antipsychotics had a negative impact on quality of life [50].

3.4.2.4 Cognition Three papers assessed the impact on cognition. Two of the papers found that the interventions, both combined medication review and education, had no impact on cognition, one paper focussed on anticholinergics over 3 months [52] and the other focussed on antipsychotics over 12 months [56]. One paper reporting a medication review intervention focussed on PIMs over 6 months found a statistically significant decline in cognition, although the authors considered this to be owing to the natural progression of dementia or MCI rather than to the intervention. Limitations in cognitive assessment were also acknowledged [48].

3.4.3 Safety-Related Outcomes

3.4.3.1 Mortality Five papers across all three intervention groups reported mortality [32, 33, 35, 41, 55], either measuring mortality rates or deaths during the study that were considered likely due to the intervention. Three papers reported studies in long-term care settings and two papers reported a study in primary care. All showed no effect [32, 33, 41, 55] or decreased mortality [35], indicating safety of the interventions.

3.4.3.2 Hospital Attendance Six papers outlined the impact of the intervention on hospital attendances and all of them were shown to be safe in so far as they had no effect or led to a non-significant decrease in hospital attendance. One paper [51] found a significant decrease in sub-group analyses that excluded patients with heart failure. The interventions were from across all three groups of interventions, in a range of settings, and focussed on various medication types.

4 Discussion

This systematic review identified 32 papers reporting interventional studies that explored outcomes of interventions to reduce polypharmacy in older people with dementia or MCI. The included papers reported interventions that incorporated either a medication review component, an education

component or both, mainly implemented in long-term care settings. The interventions had mixed effects. In line with previous reviews, medication-related outcomes were the most frequently reported outcome measure [20, 67]. There was a trend towards interventions having a positive effect on reducing the number and improving the appropriateness of medications and psychotropic prescriptions. Some interventions were considered to be safe, with either no effect or a slight improvement in mortality and hospital attendance observed. However, the effects of the interventions on BPSD, falls, quality of life and cognition were inconsistent. There was no indication that any one type of intervention worked best. In addition, none of the included studies reported the frailty status of participants and, with the exception of four studies, potentially included participants with limited life expectancy, both factors that could influence outcomes.

Most interventions focussed on medicine optimisation and deprescribing in long-term care settings or inpatient settings, with less than 20% of the papers reporting studies undertaken in primary care or community healthcare service settings. Yet, in the UK, it is estimated that 61% of people with dementia live at home, where medication is a part of daily living [68]. This limits the generalisability of the findings to community-dwelling older adults being cared for by family members, despite reports of widespread exposure to potentially inappropriate medications amongst this cohort [69, 70]. Deprescribing interventions implemented in primary and community settings have, to date, primarily focussed on older people in general and have not been specific to people with dementia or MCI [71–73].

Psychotropic medications and PIMs were the main types of medications investigated, with more than two thirds of papers reporting studies aiming to reduce prescriptions of these medications. This is in line with a recent systematic review of outcomes reported in deprescribing studies which found that the majority of studies targeted PIMs [31]. A focus on PIMs, which include many psychotropic medications, is unsurprising given that many have side effects that pose a risk for people living with dementia, such as exacerbating confusion and increasing the risk of falls [61]. Multiple tools for identifying PIMs were used, the most frequent being the internationally recognised Beers criteria [46], likely reflecting that this includes medications inappropriate for individuals with dementia or cognitive impairment, unlike other commonly used criteria such as STOPP [66].

Few papers in the review reported clinical outcomes such as BPSD, falls, cognition and quality of life. This lack of clinical outcome data has also been highlighted as a limitation in deprescribing studies to date. A 2022 review of deprescribing interventional studies amongst older people in general reported the outcome measures most commonly

used were number of medications or PIMs stopped, health-care use and adverse events [67], with patient-reported outcomes or geriatric syndromes (e.g. falls, fractures, gait speed, depression and delirium) infrequently reported. The US Deprescribing Research Network (USDeN) recommendations state that clinical outcomes should be the primary outcome assessed in deprescribing trials [67], but a recent review showed the choice of outcome was rarely justified or applied, as was the method of measurement [31]. Similarly, there is no consensus amongst researchers and clinicians on appropriate outcomes of deprescribing in people with dementia and more research is needed in this area. A recent review of 231 deprescribing RCTs found that deprescribing is a promising intervention across different settings and situations, but there is a notable gap in literature concerning its effects on health- and clinical-related outcomes [74].

The review identified limited evidence regarding the effect of deprescribing on clinical outcomes. This reflects findings from other systematic reviews of deprescribing in older adults which have shown, for example, little or inconsistent effect on cognition [75] and falls [72, 76]. Short follow-up periods may have an impact as many months may be required for certain changes, such as slowing of cognitive decline, to become clinically detectable [67]. Yet, in both this review and other reviews [72, 75, 76], many studies measured clinical outcomes for 6 months or less.

The most frequently measured clinical-related outcome was BPSD, assessed primarily in long-term care settings. This reflects both the focus on psychotropic medications and concern about overuse of antipsychotics for BPSD [77], with current guidelines suggesting that antipsychotics should not be prescribed for BPSD unless a person is severely distressed or at risk of harming themselves or others and should be reviewed at least every six weeks [78]. Indeed, the findings of this review highlight that a decrease in psychotropic medication mostly had either no effect or led to an improvement in BPSD, with only one study showing a worsening of BPSD assessed using NPI, although there was no effect on CMAI scores.

Amongst older people with dementia or MCI, a few of the included papers in this review reported safety outcomes and found that medicine optimisation and deprescribing did not adversely impact hospital attendance or mortality. A number of systematic reviews have investigated the impact of deprescribing on mortality amongst the general population of older people. One reported that deprescribing reduced mortality in non-randomised studies but no changes were observed in RCTs [12]. Other reviews suggested a reduction in all-cause mortality with deprescribing interventions in long-term care residents [79, 80] or no change in people living with frailty [23]. Overall, research therefore suggests that deprescribing is safe amongst older people, including those with dementia or MCI.

Mixed effects of medicine optimisation and deprescribing on the HRQOL amongst older people with dementia or MCI were reported in our review. These findings are consistent with literature published on older people in general [81, 82]. Possible explanations for this might be that the impact of deprescribing on HRQOL may depend on the specific combination of medication(s), setting, timing of the HRQOL measurement or the HRQOL measurement tools used. A recent scoping review included 52 papers which reported that the measurement properties of scales for capturing changes in quality of life (QoL) from deprescribing were uncertain and that because medication specific QoL scales have not been employed in deprescribing clinical trials, their performance in this context is also not clear [83]. QoL in older people is complex and might be difficult to improve with a single intervention targeting the number of prescribed medicines.

There was a general absence of measurement of cost implications of interventions, reflecting previous findings relating to deprescribing interventional research amongst older people [67]. However, although overall the review shows an absence of improvement in clinical outcomes, the lack of a worsening of outcomes and evidence that deprescribing is safe can be considered positive in respect of potential cost savings. Given the significant cost of medications and other costs relating to the prescription and dispensing of medication [84], the reduction in medications, evidenced by many of the interventions, would represent cost savings.

The number of interventions in which patients and carers were involved was limited. Only two of the interventions involving education included direct education of patients and/or carers. One of these interventions involving direct patient education showed similar levels of deprescribing for people with MCI as for those with normal cognition. However, in both the education interventions and other interventions, the views and experiences of patients and carers in relation to the intervention and the impact of the intervention on their medicine optimisation was lacking. From the patient and carer perspective, considerations such as treatment burden and optimising quality of life are likely to be important, yet HRQOL was only reported in three papers. Further research is required on how shared decision-making can be achieved and its impact on outcomes, especially for those individuals living in their own home. There is a need, therefore, to integrate person-centred and contextual factors (such as an individual's condition and circumstances) into deprescribing decision-making models [85]. This requires tools to support tailored deprescribing for people with dementia and MCI, although the evidence base needed to underpin these has previously been reported to be of generally low or moderate quality [20].

4.1 Strengths and Limitations

This is the first systematic review to bring together the evidence on this important topic. The review used robust methodology, following a protocol using the PRISMA statement methods and being registered on PROSPERO. A comprehensive search strategy allowed inclusion of all relevant studies from database inception to January 2024 and identified a large number of interventional studies in this population. However, there is the potential that some papers were missed owing to searching the Medline database rather than PubMed. The heterogeneity of the included studies, with a wide variation of study designs, settings and outcome measurements meant robust quantitative synthesis was not possible. Although the interventions were grouped to manage the data, each group included a range of interventional approaches. This review also confirms a continued lack of robust evidence, particularly for deprescribing in primary and community care services. The focus on long-term care, PIMs and psychotropic medications in the included papers limits the generalisability of the findings to settings such as primary and community services. The assessed quality of the included papers varied from quite low to high, with only four RCTs (eight papers) included in the review.

4.2 Future Research

Given the complex and context-specific nature of deprescribing for people with dementia and MCI, this review highlights the fact that further research is needed, particularly in settings other than long-term care. Future RCTs should focus on reporting the impact of deprescribing on clinical outcomes where longer follow-up periods are included. Further research is also required to understand how a shared decision approach to deprescribing involving patients, carers and healthcare professionals can be achieved and assessed for its impact. Healthcare professionals may benefit from tools to support SDM [86] and to help them balance the benefits and risks, but these tools require more robust evidence to inform them.

5 Conclusions

This review provides the first systematic assessment of the effects of medicine optimisation and deprescribing interventions for older people with dementia or MCI. The findings show that many interventions were effective in reducing numbers of medications and PIMs. However, evidence on safety and clinical outcomes was more limited, although studies measuring safety outcomes demonstrated that deprescribing was safe. An absence of worsening of clinical

outcomes is indicative of potential cost savings. There was a paucity of research outside of institutional settings and no evidence that any one type of intervention worked best. Future designs of deprescribing interventions need to involve patients and carers and tailored, evidence-based deprescribing tools to ensure their needs are met, as well as those of healthcare professionals. Given an aging population and associated increase in the prevalence of dementia, and the potential harms of over-prescribing and inappropriate polypharmacy in this vulnerable group, there is an urgent need for further high-quality research, particularly in primary care and community service settings.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s40266-025-01189-2>.

Acknowledgements We thank Paula Sands, the Faculty of Medicine Librarian, for her support in developing the search strategies.

Declarations

Funding This study was funded by the National Institute for Health and Care Research Applied Research Collaboration Wessex. The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health and Care Research or the Department of Health and Social Care.

Conflict of Interests The authors have no competing interests to declare that are relevant to the content of this article.

Availability of Data and Material Data supporting the findings of this study are available within the paper and its Supplementary Information.

Ethics Approval Not applicable.

Consent to Participate Not applicable.

Code Availability Not applicable.

Consent for Publication Not applicable.

Author Contributions N.A., M.B., S.F., S.L., J.A., R.L. and K.I. contributed to the conception and design of the review. N.A., C.B., S.F., K.A., B.M., J.A., R.L., E.v.L. and K.I. completed literature search and screening. N.A., C.B., M.B., S.L., K.A., R.L. and K.I. extracted data from included papers. M.B. and E.R. assessed the quality of the papers. N.A. drafted the manuscript, and all the authors revised and edited the manuscript. All the authors read and approved the final manuscript.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

References

1. Clague F, Mercer SW, McLean G, Reynish E, Guthrie B. Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data. *Age Ageing*. 2017;46:33–9.
2. Park HY, Park JW, Song HJ, Sohn HS, Kwon JW. The association between polypharmacy and dementia: a nested case-control study based on a 12-year longitudinal cohort database in South Korea. *PLoS ONE*. 2017. <https://doi.org/10.1371/journal.pone.0169463>.
3. Mueller C, Molokhia M, Perera G, Veronese N, Stubbs B, Shetty H, et al. Polypharmacy in people with dementia: associations with adverse health outcomes. *Exp Gerontol*. 2018;106:240–5.
4. Onder G, Liperoti R, Foebel A, Fialova D, Topinkova E, van der Roest HG, et al. Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: results from the SHELTER study. *J Am Med Dir Assoc*. 2013. <https://doi.org/10.1016/j.jamda.2013.03.014>.
5. Ramsey CM, Gnjdici D, Agogo GO, Allore H, Moga D. Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. *Alzheimers Dement TRCI*. 2018. <https://doi.org/10.1016/j.trci.2017.10.008>.
6. Thorell K, Midlov P, Fastbom J, Halling A. Use of potentially inappropriate medication and polypharmacy in older adults: a repeated cross-sectional study. *BMC Geriatr*. 2020. <https://doi.org/10.1186/s12877-020-1476-5>.
7. Johnell K. Inappropriate drug use in people with cognitive impairment and dementia: a systematic review. *Curr Clin Pharmacol*. 2015;10:178–84.
8. Lim RH, Sharmeen T. Medicines management issues in dementia and coping strategies used by people living with dementia and family carers: a systematic review. *Int J Geriatr Psychiatry*. 2018. <https://doi.org/10.1002/gps.4985>.
9. Maidment I, Lawson S, Wong G, Booth A, Watson A, Zaman H, et al. Towards an understanding of the burdens of medication management affecting older people: the MEMORABLE realist synthesis. *BMC Geriatr*. 2020. <https://doi.org/10.1186/s12877-020-01568-x>.
10. Brandt NJ. Optimizing medication use through deprescribing: tactics for this approach. *J Gerontol Nurs*. 2016. <https://doi.org/10.3928/00989134-20151218-08>.
11. Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? *Can J Hosp Pharm*. 2013;66:201–2.
12. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. *Br J Clin Pharmacol*. 2016. <https://doi.org/10.1111/bcp.12975>.
13. Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. *Drugs Aging*. 2008;25:1021–31.
14. van der Cammen TJ, Rajkumar C, Onder G, Sterke CS, Petrovic M. Drug cessation in complex older adults: time for action. *Age Ageing*. 2014. <https://doi.org/10.1093/ageing/aft166>.
15. Thio SL, Nam J, van Driel ML, Dirven T, Blom JW. Effects of discontinuation of chronic medication in primary care: a systematic review of deprescribing trials. *Br J Gen Pract*. 2018. <https://doi.org/10.3399/bjgp18X699041>.
16. Reeve E. Deprescribing tools: a review of the types of tools available to aid deprescribing in clinical practice. *J Pharm Pract Res*. 2020. <https://doi.org/10.1002/jppr.1626>.
17. Ulley J, Harrop D, Ali A, Alton S, Fowler DS. Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: a systematic review. *BMC Geriatr*. 2019. <https://doi.org/10.1186/s12877-019-1031-4>.

18. World Health Organization. Medication without harm: policy brief. 2023. <https://www.who.int/publications/i/item/9789240062764>. Accessed 14 Oct 2024.
19. National Institute for Health and Care Excellence (NICE). Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. NICE guideline (NG5). 2015. <https://www.nice.org.uk/guidance/ng5>. Accessed 14 Oct 2024.
20. Sawan MJ, Moga DC, Ma MGJ, Ng JC, Johnell K, Gnjdjic D. The value of deprescribing in older adults with dementia: a narrative review. *Expert Rev Clin Pharmacol*. 2021. <https://doi.org/10.1080/17512433.2021.1961576>.
21. Trevisan C, Limongi F, Siviero P, Noale M, Cignarella A, Manzato E, et al. Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions. *Aging Clin Exp Res*. 2021. <https://doi.org/10.1007/s40520-019-01420-2>.
22. Omuya H, Nickel C, Wilson P, Chewning B. A systematic review of randomised-controlled trials on deprescribing outcomes in older adults with polypharmacy. *Int J Pharm Pract*. 2023. <https://doi.org/10.1093/ijpp/riad025>.
23. Ibrahim K, Cox NJ, Stevenson JM, Lim S, Fraser SDS, Roberts HC. A systematic review of the evidence for deprescribing interventions among older people living with frailty. *BMC Geriatr*. 2021. <https://doi.org/10.1186/s12877-021-02208-8>.
24. Reeve E, Bell JS, Hilmer SN. Barriers to optimising prescribing and deprescribing in older adults with dementia: a narrative review. *Curr Clin Pharmacol*. 2015. <https://doi.org/10.2174/157488471003150820150330>.
25. Growdon ME, Espejo E, Jing B, Boscardin WJ, Zullo AR, Yaffe K, et al. Attitudes toward deprescribing among older adults with dementia in the United States. *J Am Geriatr Soc*. 2022. <https://doi.org/10.1111/jgs.17730>.
26. Harrison SL, Cations M, Jessop T, Hilmer SN, Sawan M, Brodaty H. Approaches to deprescribing psychotropic medications for changed behaviours in long-term care residents living with dementia. *Drugs Aging*. 2019. <https://doi.org/10.1007/s40266-018-0623-6>.
27. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffman TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Br Med J*. 2021. <https://doi.org/10.1136/bmj.n71>
28. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. *Syst Rev*. 2016. <https://doi.org/10.1186/s13643-016-0384-4>.
29. Hong QN, Pluye P, Fàbrgues S, Bartlett G, Boardman F, Cargo M, et al. Mixed Methods Appraisal Tool (MMAT) version 2018. 2018; <https://www.nccmt.ca/knowledge-repositories/search/232>. Accessed 14 Oct 2024.
30. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. *Br Med J*. 2020. <https://doi.org/10.1136/bmj.l6890>.
31. Nizet P, Evin A, Brociero E, Vigneau CV, Huon J-F. Outcomes in deprescribing implementation trials and compliance with expert recommendations: a systematic review. *BMC Geriatr*. 2023. <https://doi.org/10.1186/s12877-023-04155-y>.
32. Boyd CM, Shetterly SM, Powers JD, Weffald LA, Green AR, Sheehan OC, et al. Evaluating the safety of an educational deprescribing intervention: lessons from the Optimize trial. *Drugs Aging*. 2024. <https://doi.org/10.1007/s40266-023-01080-y>.
33. Bayliss EA, Shetterly SM, Drace ML, Norton JD, Maiyani M, Gleason KS, et al. Deprescribing education vs usual care for patients with cognitive impairment and primary care clinicians: the OPTIMIZE pragmatic cluster randomized trial. *JAMA Int Med*. 2022. <https://doi.org/10.1001/jamainternmed.2022.0502>.
34. Molist Brunet N, Sevilla-Sanchez D, Amblàs Novellas J, Codina Jané C, Gomez-Batiste X, McIntosh J, et al. Optimizing drug therapy in patients with advanced dementia: a patient-centered approach. *Eur Geriatr Med*. 2014. <https://doi.org/10.1016/j.eurger.2013.10.011>.
35. Cossette B, Bruneau MA, Couturier Y, Gilbert S, Boyer D, Ricard J, et al. Optimizing practices, use, care and services-antipsychotics (OPUS-AP) in long-term care centers in Quebec, Canada: a strategy for best practices. *J Am Med Dir Assoc*. 2020. <https://doi.org/10.1016/j.jamda.2019.08.027>.
36. Cossette B, Bruneau MA, Morin M, Gilbert S, Boyer D, MacDonald T, et al. Optimizing practices, use, care, and services-antipsychotics (OPUS-AP) in long-term care centers in Quebec, Canada: a successful scale-up. *J Am Med Dir Assoc*. 2022. <https://doi.org/10.1016/j.jamda.2021.12.031>.
37. Wilchesky M, Mueller G, Morin M, Marcotte M, Voyer P, Aubin M, et al. The OptimaMed intervention to reduce inappropriate medications in nursing home residents with severe dementia: results from a quasi-experimental feasibility pilot study. *BMC Geriatr*. 2018. <https://doi.org/10.1186/s12877-018-0895-z>.
38. Kröger E, Wilchesky M, Morin M, Carmichael PH, Marcotte M, Misson L, et al. The OptimaMed intervention to reduce medication burden in nursing home residents with severe dementia: results from a pragmatic, controlled study. *BMC Geriatr*. 2023. <https://doi.org/10.1186/s12877-023-04222-4>.
39. Maidment ID, Barton G, Campbell N, Shaw R, Seare N, Fox C, et al. MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention. *BMC Health Serv Res*. 2020. <https://doi.org/10.1186/s12913-020-5014-0>.
40. Martin P, Tannenbaum C. Use of the EMPOWER brochure to deprescribe sedative-hypnotic drugs in older adults with mild cognitive impairment. *BMC Geriatr*. 2017. <https://doi.org/10.1186/s12877-017-0432-5>.
41. Weeks WB, Mishra MK, Curto D, Petersen CL, Cano P, Hsuen Y, et al. Comparing three methods for reducing psychotropic use in older demented Spanish care home residents. *J Am Geriatr Soc*. 2019;67(7):1444–53.
42. Liu AK, Possin KL, Cook KM, Lynch S, Dulaney S, Merrilees JJ, et al. Effect of collaborative dementia care on potentially inappropriate medication use: outcomes from the care ecosystem randomized clinical trial. *Alzheimer's Dement*. 2022. <https://doi.org/10.1002/alz.12808>.
43. Maidment ID, Shaw RL, Killick K, Damery S, Hilton A, Wilcock J, et al. Improving the management of behaviour that challenges associated with dementia in care homes: protocol for pharmacy-health psychology intervention feasibility study. *BMJ Open*. 2016. <https://doi.org/10.1136/bmjopen-2015-010279>.
44. Silva-Almodovar AA, Malfara A, Nahata MC. Impact of automated targeted medication review electronic alerts to reduce potentially inappropriate medication prescribing among medicare enrolled patients with dementia. *Ann Pharmacother*. 2020. <https://doi.org/10.1177/1060028020915790>.
45. Smeets CHW, Smalbrugge M, Koopmans RTCM, Nelissen-Vrancken MHJM, van der Spek K, Teerenstra S, et al. Can the PROPER intervention reduce psychotropic drug prescription in nursing home residents with dementia? Results of a cluster-randomized controlled trial. *Int Psychogeriatr*. 2021. <https://doi.org/10.1017/S1041610220000629>.
46. van der Spek K, Koopmans RTCM, Smalbrugge M, Nelissen-Vrancken MHJM, Wetzels RB, Smeets CHW, et al. The effect of biannual medication reviews on the appropriateness of psychotropic drug use for neuropsychiatric symptoms in patients with dementia: a randomised controlled trial. *Age Ageing*. 2018. <https://doi.org/10.1093/ageing/afy001>.
47. Sakakibara M, Igrashi A, Takekese Y, Kamei H, Nabeshima T. Effects of prescription drug reduction on quality of life in

- community-dwelling patients with dementia. *J Pharm Pharm Sci*. 2015. <https://doi.org/10.18433/j37p5x>.
48. Coli KG, Lee M, Aladeen TS, Mattle AG, Ajtai B, Rainka MM. Impact of medication optimization and recommendations by clinical pharmacists embedded in a memory disorder clinic. *J Am Coll Clin Pharm*. 2022. <https://doi.org/10.1002/jac5.1744>.
 49. Gustafsson M, Sjolander M, Pfister B, Schneede J, Lovheim H. Effects of pharmacists' interventions on inappropriate drug use and drug-related readmissions in people with dementia—a secondary analysis of a randomized controlled trial. *Pharmacy*. 2018. <https://doi.org/10.3390/pharmacy6010007>.
 50. Ballard C, Orrell M, Sun Y, Moniz-Cook E, Stafford J, Whitaker R, et al. Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD—a factorial cluster randomised controlled trial. *Int J Geriatr Psychiatry*. 2017. <https://doi.org/10.1002/gps.4572>.
 51. Gustafsson M, Sjolander M, Pfister B, Jonsson J, Schneede J, Lovheim H. Pharmacist participation in hospital ward teams and hospital readmission rates among people with dementia: a randomized controlled trial. *Eur J Clin Pharmacol*. 2017. <https://doi.org/10.1007/s00228-017-2249-8>.
 52. Yeh YC, Liu CL, Peng LN, Lin MH, Chen LK. Potential benefits of reducing medication-related anticholinergic burden for demented older adults: a prospective cohort study. *Geriatr Gerontol Int*. 2013. <https://doi.org/10.1111/ggi.12000>.
 53. Bravo-Jose P, Saez-Lleo CI, Peris-Marti JF. Deprescribing antipsychotics in long term care patients with dementia. *Farm Hosp*. 2019. <https://doi.org/10.7399/fh.11217>.
 54. Jaïdi Y, Nonnonhou V, Kanagaratnam L, Bertholon LA, Badr S, Noël V, et al. Reduction of the anticholinergic burden makes it possible to decrease behavioral and psychological symptoms of dementia. *Am J Geriatr Psychiatry*. 2018. <https://doi.org/10.1016/j.jagp.2017.08.005>.
 55. Ballard C, Orrell M, YongZhong S, Moniz-Cook E, Stafford J, Whittaker R, et al. Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the Well-Being and Health for People with Dementia (WHELD) program. *Am J Psychiatry*. 2016. <https://doi.org/10.1176/appi.ajp.2015.15010130>.
 56. Brodaty H, Aerts L, Harrison F, Jessop T, Cations M, Chenoweth L, et al. Antipsychotic deprescription for older adults in long-term care: the HALT study. *J Am Med Dir Assoc*. 2018. <https://doi.org/10.1016/j.jamda.2018.05.002>.
 57. Massot Mesquida M, Tristany Casas M, Franzi Siso A, Garcia Munoz I, Hernandez Vian O, Toran MP. Consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients. *BMC Geriatr*. 2019. <https://doi.org/10.1186/s12877-018-1015-9>.
 58. Muniz R, Perez-Webbe AI, Couto F, Perez M, Ramirez N, Lopez A, et al. The “CHROME criteria”: tool to optimize and audit prescription quality of psychotropic medications in institutionalized people with dementia. *Int Psychogeriatr*. 2020. <https://doi.org/10.1017/S104161021900111X>.
 59. Muniz R, Lopez-Alvarez J, Perea L, Rivera S, Gonzalez L, Olazaran J. CHROME criteria and quality of life: a pilot study from Maria Wolff-Albertia. *J Alzheimer's Dis Rep*. 2021. <https://doi.org/10.3233/ADR-210015>.
 60. Andrew MK, Purcell CA, Marshall EG, Varatharasan, Clarke B, Bowles SK. Polypharmacy and use of potentially inappropriate medications in long-term care facilities: does coordinated primary care make a difference? *Int J Pharm Pract*. 2018; <https://doi.org/10.1111/ijpp.12397>
 61. Kable A, Fraser S, Fullerton A, Hullick C, Palazzi K, Oldmeadow C, et al. Evaluation of the effect of a safe medication strategy on potentially inappropriate medications, polypharmacy and anticholinergic burden for people with dementia: an intervention study. *Healthcare*. 2023. <https://doi.org/10.3390/healthcare11202771>.
 62. Pearson SM, Osbaugh NA, Linnebur SA, Fixen DR, Brungardt A, Marcus AM, et al. Implementation of pharmacist reviews to screen for potentially inappropriate medications in patients with cognitive impairment. *Sr Care Pharm*. 2021. <https://doi.org/10.4140/TCP.n.2021.508>.
 63. Pasina L, Marengoni A, Ghibelli S, Suardi F, Djade CD, Nobili A, et al. A multicomponent intervention to optimize psychotropic drug prescription in elderly nursing home residents: an Italian multicenter, prospective, pilot study. *Drugs Aging*. 2016. <https://doi.org/10.1007/s40266-015-0336-z>.
 64. Walsh KA, Byrne S, O'Riordan A, McSharry J, Browne J, Irving K, et al. Rationalising antipsychotic prescribing in dementia (RAPID) complex intervention: a mixed-methods feasibility intervention study. *Explor Res Clin Soc Pharm*. 2022. <https://doi.org/10.1016/j.rcsop.2022.100190>.
 65. 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers criteria (R) for potentially inappropriate medication use in older adults. *J Am Geriatr Soc*. 2023; <https://doi.org/10.1111/jgs.18372>
 66. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015. <https://doi.org/10.1093/ageing/afu145>.
 67. Bayliss EA, Albers K, Gleason K, Pieper LE, Boyd CM, Campbell NL, et al. Recommendations for outcome measurement for deprescribing intervention studies. *J Am Geriatr Soc*. 2022. <https://doi.org/10.1111/jgs.17894>.
 68. Prince M, Knapp M, Guerchet M, McCrone P, Prina M, Comas-Herrera M, et al. Dementia UK: update. *Alzheimer's Society*; 2014.
 69. Gnjdjic D, Agogo GO, Ramsey CM, Moga DC, Allore H. The impact of dementia diagnosis on patterns of potentially inappropriate medication use among older adults. *J Gerontol A-Biol Sci Med Sci*. 2018. <https://doi.org/10.1093/gerona/gly078>.
 70. Renom-Guiteras A, Thurmann PA, Miralles R, Klassen-Mielke R, Thiem U, Stephan A, et al. Potentially inappropriate medication among people with dementia in eight European countries. *Age Ageing*. 2018. <https://doi.org/10.1093/ageing/afx147>.
 71. Clyne B, Fitzgerald C, Quinlan A, Hardy C, Galvin R, Fahey T, et al. Interventions to address potentially inappropriate prescribing in community-dwelling older adults: a systematic review of randomized controlled trials. *J Am Geriatr Soc*. 2016. <https://doi.org/10.1111/jgs.14133>.
 72. Bloomfield HE, Greer N, Linsky AM, Bolduc J, Naidl T, Vardeny O, et al. Deprescribing for community-dwelling older adults: a systematic review and meta-analysis. *J Gen Intern Med*. 2020. <https://doi.org/10.1007/s11606-020-06089-2>.
 73. Radcliffe E, Servin R, Cox N, Lim S, Tan QY, Howard C, et al. What makes a multidisciplinary medication review and deprescribing intervention for older people work well in primary care? A realist review and synthesis. *BMC Geriatr*. 2023. <https://doi.org/10.1186/s12877-023-04256-8>.
 74. Veronese N, Gallo U, Boccardi V, Demurtas J, Michielon A, Taci X, et al. Efficacy of deprescribing on health outcomes: an umbrella review of systematic reviews with meta-analysis of randomized controlled trials. *Ageing Res Rev*. 2024. <https://doi.org/10.1016/j.arr.2024.102237>.
 75. Liu BM, Redston MR, Fujita K, Thillainadesan J, Gnjdjic D, Hilmer S. The impact of deprescribing interventions on the Drug Burden Index and other outcomes: a systematic review. *J Am Med Dir Assoc*. 2024;25(7): 105021.

76. Lee J, Negm A, Peters R, Wong EKC, Holbrook A. Deprescribing for fall-risk increasing drugs (FRIDs) for the prevention of falls and fall-related complications: a systematic review and meta-analysis. *BMJ Open*. 2021. <https://doi.org/10.1136/bmjopen-2019-035978>.
77. Banerjee S. The use of antipsychotic medication for people with dementia: time for action. Department of Health; 2009.
78. National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers: NICE guideline [NG97]. 2018; <https://www.nice.org.uk/guidance/ng97>. Accessed 14 Oct 2024.
79. Almutairi H, Stafford A, Etherton-Beer C, Flicker L. Optimisation of medications used in residential aged care facilities: a systematic review and meta-analysis of randomised controlled trials. *BMC Geriatr*. 2020. <https://doi.org/10.1186/s12877-020-01634-4>.
80. Kua S, Mak VSL, Huey Lee SW. Health outcomes of deprescribing interventions among older residents in nursing homes: a systematic review and meta-analysis. *J Am Med Dir Assoc*. 2019. <https://doi.org/10.1016/j.jamda.2018.10.026>.
81. Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy for older people. *Cochrane Database Syst Rev*. 2018. <https://doi.org/10.1002/14651858.CD008165.pub4>.
82. Pruskowski JA, Springer S, Thorpe CT, Klein-Fedyshin M, Handler SM. Does deprescribing improve quality of life? A systematic review of the literature. *Drugs Aging*. 2019. <https://doi.org/10.1007/s40266-019-00717-1>.
83. Thompson W, Lundby C, Bleik A, Waring H, Hong JA, Xi C, et al. Measuring quality of life in deprescribing trials: a scoping review. *Drugs Aging*. 2024. <https://doi.org/10.1007/s40266-024-01113-0>.
84. NHS Business Services Authority. Prescribing costs in hospitals and the community - England 2018/19 to 2022/23. 2023. <https://www.nhsbsa.nhs.uk/statistical-collections/prescribing-costs-hospitals-and-community-england/prescribing-costs-hospitals-and-community-england-202122/prescribing-costs-hospitals-and-community-england-201819-202223>. Accessed 14 Oct 2024.
85. Reeve J, Maden M, Hill R, Turk A, Mahtani K, Wong G, et al. Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis. *Health Technol Assess*. 2022. <https://doi.org/10.3310/AAFO2475>.
86. Chenoweth L. Supporting shared decision-making in medicines use with people living with dementia and their carers. *Nurs Older People*. 2024. <https://doi.org/10.7748/nop.2024.e1458>.

Authors and Affiliations

Nicola Andrews^{1,2}  · Cindy Brooks^{1,2}  · Michele Board³ · Simon Fraser^{2,4} · Sue Latter¹ · Kirsty Aplin⁵ · Beth McCausland^{5,6} · Eloise Radcliffe^{2,4}  · Jay Amin^{5,6} · Rosemary Lim⁷  · Ellen van Leeuwen^{8,9}  · Kinda Ibrahim^{2,4} 

✉ Kinda Ibrahim
k.ibrahim@soton.ac.uk

- ¹ School of Health Sciences, University of Southampton, Southampton, UK
- ² National Institute of Health and Care Research (NIHR) Applied Research Collaboration Wessex, Southampton, UK
- ³ Ageing and Dementia Research Centre, Bournemouth University, Bournemouth, UK
- ⁴ School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK

- ⁵ Memory Assessment and Research Centre, Southern Health NHS Foundation Trust, Southampton, UK
- ⁶ School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
- ⁷ Reading School of Pharmacy, University of Reading, Reading, UK
- ⁸ Department of Basic and Applied Medical Sciences, Ghent University, Ghent, Belgium
- ⁹ Department of Public Health and Primary Care, Ghent University, Ghent, Belgium